Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Nelivaptan
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
HMNC Brain Health Completes Patient Randomization for OLIVE Trial in Depression
Details : BH-200 (nelivaptan) is a potent vasopressin V1b receptor antagonist, being investigated in patients with Major Depressive Disorder (MDD).
Product Name : BH-200
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 10, 2025
Lead Product(s) : Nelivaptan
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Develco Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : KET01 is an oral prolonged-release ketamine formulation, a rapid-acting general anesthetic and NMDA receptor antagonist used for induction of anesthesia typically in combination with a muscle relaxant. It is being currently developed for treatment-resist...
Product Name : KET01
Product Type : Controlled Substance
Upfront Cash : Inapplicable
August 14, 2023
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Develco Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nelivaptan
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BH-200 (nelivaptan) is a potent vasopressin V1b receptor antagonist, for improved treatment of patients with MDD who have underlying HPA-axis (Hypothalamus‐pituitary‐adrenal axis) dysfunction.
Product Name : BH-200
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 20, 2023
Lead Product(s) : Nelivaptan
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
First Patient Dosed in Second Phase 2 Add-On Ketamine Trial in Treatment-Resistant Depression (TRD)
Details : The trial will assess the efficacy, safety, and tolerability of add-on treatment with Ketamine hydrochloride prolonged-release tablets (KET01) in patients suffering from Treatment-Resistant depression (TRD).
Product Name : KET01
Product Type : Controlled Substance
Upfront Cash : Inapplicable
August 06, 2022
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Develco Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Data suggest that KET01 is rapidly acting with a clinically meaningful improvement compared with placebo already after 7 days, which stands in sharp contrast to standard antidepressants which have a delayed onset of action of up to several weeks.
Product Name : KET01
Product Type : Controlled Substance
Upfront Cash : Inapplicable
March 31, 2022
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Develco Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Develco Pharma
Deal Size : Undisclosed
Deal Type : Partnership
Details : HMNC and Develco Pharma have created a joint venture and formed the company Ketabon, which will initiate a Contract Research Organization led proof-of-concept study of an investigational oral prolonged-release formulation of ketamine targeting treatment-...
Product Name : KET01
Product Type : Controlled Substance
Upfront Cash : Undisclosed
August 24, 2021
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Develco Pharma
Deal Size : Undisclosed
Deal Type : Partnership